ClinicalTrials.gg
RecruitingNCT04144231SLEEPINSUpdated Oct 10, 2023

Cognitive Behavioral Therapy for Insomnia (CBT-I) in Schizophrenia(SLEEPINS)

An interventional study of iCBT-I and GCBT-I in Insomnia, Schizophrenia and Schizoaffective Disorder, sponsored by Helsinki University Central Hospital. Recruiting at 1 site in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Helsinki University Central Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Dec 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Sleep Initiation and Maintenance Disorders with a site in Finland — 3 open to participants now, 4 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Finland.

Planned enrollment
13th of 16
120 · median 367
Started
2019
the only one that year
No phase
6 of 16
3 open now
Registered
11th of 16
by date
Lead sponsor
3 of 16
Helsinki University Central Hospital

Among the 16 studies in Sleep Initiation and Maintenance Disorders with a site in Finland, this one is the 13th largest by planned enrollment, is the only one that started in 2019, is one of 6 with no phase, and was the 11th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

3 of the 16 studies in Sleep Initiation and Maintenance Disorders with a site in Finland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Sleep Initiation and Maintenance Disorders with a site in Finland, or all of them as a file.
02

Study summary

Sleep problems are pervasive in people with schizophrenia. In our study, our goal is to determine whether we can alleviate sleep symptoms and improve quality of life and well-being in patients with major psychiatric disorders through cognitive behavioral therapy (CBT) delivered via the internet or in groups.

At the same time, the study provides information on factors that are commonly associated with sleep and well-being in patients. The intervention study is conducted as a Randomized Controlled Clinical Trial (RCT), in which subjects are randomized into three groups: 1) Treatment as usual (TAU), 2) TAU and Internet-based therapy for insomnia (ICBT-I), and 3) TAU and group therapy for insomnia (GCBT-I).

Read the detailed description

Sleep is important for well-being. Lack of sleep and poor quality of sleep (Insomnia) are risk factors for psychiatric and somatic diseases such as depression, cardiovascular disease, diabetes and memory disorders and increases the risk of cognitive errors and accidents.

Psychiatric patients suffer from a wide variety of sleep disorders. Insomnia symptoms are known to increase the likelihood of later depression and even the use of disability pensions due to depression.

Various sleep disorders are also common in patients with schizophrenia. Previous studies on schizophrenia have reported-, symptoms of insomnia, especially the problem of falling asleep and poor sleep quality, circadian rhythm disruption, hypersomnolence and nightmares among the patients.

Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based treatment for insomnia. CBT-I can be implemented as an individual treatment, on a group basis or via the internet. There is evidence that CBT-I can also be used to treat a patient with a major psychiatric disorders, but randomized clinical trials (RCT) have rarely been published. Our research is based on the hypothesis that symptoms of insomnia in patients with schizophrenia can improved by CBT-I and, further, by improving patients' sleep quality their health and quality of life can also be improved.

The present study is designed to investigate the effect of two different treatment programs as compared to treatment as usual (TAU). The purpose of this study is to determine whether CBT-I can help relieve sleep symptoms and improve quality of life and well-being in patients with schizophrenia. At the same time, the study provides information on factors that are commonly associated with sleep and well-being in patients with major psychiatric disorders. The intervention study is conducted as an RCT, in which subjects are randomized into three groups: 1) Treatment as usual (TAU), 2) TAU and Internet-based therapy for insomnia (ICBT-I), and 3) TAU and group therapy for insomnia (GCBT-I).

The aim of this ongoing randomized controlled trial is to recruit 84 - 120 participants from Hospital District of Helsinki and Uusimaa (HUS) Psychiatry Outpatient Clinics for Psychosis, and they have previously participated in the nationwide SUPER Finland study (a study on genetic mechanisms of psychotic disorders and a part of the Stanley Global Neuropsychiatric Genomics Initiative). The study is performed on a cycle basis with a target of 12 to 24 patients per cycle, randomly assigned to three intervention groups.

03

Conditions studied

  • Insomnia
  • Schizophrenia
  • Schizoaffective Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

To participate in the study, patients must meet the following criteria:

  1. Have previously participated in the nationwide SUPER Finland study (www.superfinland.fi, a study on genetic mechanisms of psychotic disorders and a part of the Stanley Global Initiative) and have given permission for subsequent contact.
  2. Be currently in psychiatric care at HUS
  3. Be 18 years of age or older
  4. Have a serious mental disorder (schizophrenia or schizoaffective disorder)
  5. Have a stable medical condition
  6. Have self-reported sleep problems: difficulty falling asleep, difficulty staying asleep, poor quality of sleep, or dissatisfaction with sleep
  7. Have access to an electronic inquiry and treatment program and use of e-mail
  8. Be able to participate in a sleep group if randomized.

Exclusion Criteria:

Exclusion criteria include:

  1. ongoing cognitive-behavioral psychotherapy
  2. diagnosed sleep disorder such as sleep apnea
  3. insufficient Finnish language skills (insomnia interventions are produced in Finnish, so good Finnish language skills are required)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • No intervention
    Treatment-as-usual (TAU)

    Treatment-as-usual (TAU) delivered by psychiatrists and psychiatric nurses in HUS Psychiatry Outpatient Clinic for Psychosis. Participants who randomized to TAU -group, may receive medication for insomnia, but they will not received CBT-I. Treatment-as-usual is included in all intervention groups.

  • Experimental
    Internet-Based Cognitive Behavioral Therapy for Insomnia

    TAU and Internet-Based Cognitive Behavioral Therapy for Insomnia (iCBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I): There will be seven manualized sessions, conducted at intervals of either every one or two weeks. HUS iCBT-I, is based on the same theoretical model of insomnia as described in Morin 2003 and Edinger 2015- and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. iCBT-I consists of psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep. During the therapy, the therapist monitors progress at least once a week, sends messages to the participant, and answers any treatment-related questions. The aim of the feedback is to comment on exercises, clarify intervention and motivate the patient to persist the in carrying out the treatment and the requested behavioral changes.

    Behavioral: iCBT-I

  • Experimental
    Cognitive Behavioral Group Therapy for Insomnia

    TAU and Cognitive Behavioral Group Therapy for Insomnia (GCBT-I): There will be six 90-minute manualized sessions, conducted at intervals of either one or two weeks. One booster session will be conducted one month after the treatment. Each group will have 4-8 people. The content of the CBT-I group is based on CBT for insomnia (as described above) and a previously published insomnia treatment manual for psychotic patients (Waters 2017).To ensuring the rights, safety and wellbeing of participants during the COVID-19 (Coronavirus) pandemic, we produce GCBT-I via internet.

    Behavioral: GCBT-I

Interventions

  • BehavioraliCBT-I

    Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)

  • BehavioralGCBT-I

    Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)

06

What researchers measure

Primary outcomes

  1. Change in Insomnia Severity Index score (ISI) (Morin 2011)

    A 7-item questionnaire used to assess insomnia severity with a score ranging between 0 to 28. Each questionnaire item addresses an aspect about sleep that is rated by the respondent on a 5-point scale (i.e., 0=no problem to 4=very severe problem).

    Time frame: baseline, 12, 24 and 36 weeks from the baseline

  2. Change in the health-related quality of life (HRQoL) instrument 15D score (Sintonen, 2001)

    The 15D is a generic, comprehensive, 15-dimensional, standardized, self-administered measure of health-related quality of life (HRQoL) that can be used both as a profile and single index score measure. The maximum score is 1 (no problems on any dimension) and the minimum score is 0 (being dead).

    Time frame: baseline, 12, 24 and 36 weeks from the baseline

Secondary outcomes

  1. Self-reported subjective sleep quality collected through a digital smartphone app (AIDO Healthcare)

    1-2 times a week by emoji scale 1-5

    Time frame: baseline to week 36

  2. Self-reported subjective fatigue collected through a digital smartphone app (AIDO Healthcare)

    1-2 times a week by emoji scale 1-5

    Time frame: baseline to week 36

  3. Self-reported subjective mood collected through a digital smartphone app (AIDO Healthcare)

    1-2 times a week by emoji scale 1-5

    Time frame: baseline to week 36

  4. Self-reported variables for sleep quantity and quality (adapted from Partinen 1996)

    Questions about sleep quantity and quality

    Time frame: baseline, 12, 24 and 36 weeks from the baseline

  5. Self-reported variables for chronotype (Horne 1976)

    Questions about chronotype (morningness-eveningness-)

    Time frame: baseline, 12, 24 and 36 weeks from the baseline

  6. Self-reported variables for dreaming and nightmares (adapted from Sandman 2015)

    Questions about dreaming and nightmares

    Time frame: baseline, 12, 24 and 36 weeks from the baseline

  7. Self-reported variables for tiredness, fatigue, subjective memory, stress and recovery (Lundqvist 2016)

    Questions about tiredness, fatigue, subjective memory, stress and recovery. Scale 1(very good) to 5(very poor).

    Time frame: baseline, 12, 24 and 36 weeks from the baseline

  8. Self-reported variables for functional ability (adapted from Tuomi 1998).

    Questions about functional ability. Scale 0(very poor) to 10(very good).

    Time frame: baseline, 12, 24 and 36 weeks from the baseline

  9. Self-reported variables for symptoms of depression (Korenke 2001)

    Questions about symptoms of depression. Scale 0(not at all) to 3 (Almost Always)

    Time frame: baseline, 12, 24 and 36 weeks from the baseline

  10. Self-reported variables for symptoms of psychosis (adapted from Haddoc 1999),

    Questions about presence, severity, and characteristics of hallucinations, delusions, confused and disturbed thoughts and lack of insight and self-awareness.

    Time frame: baseline, 12, 24 and 36 weeks from the baseline

  11. Self-reported variables for lifestyle

    Questions about exercise, usage of caffeine, alcohol, nicotine.

    Time frame: baseline, 12, 24 and 36 weeks from the baseline

  12. Subjective measures of Dysfunctional Beliefs and Attitudes about Sleep (DBAS-16) (Morin 2007)

    DBAS-16 is a 16-item self reported questionnaire to measure people's beliefs and attitudes about their personal sleep situations. Items are ranked from 0, strongly disagree, to 10, strongly agree. Total score is mean of all questions, with a higher score representing more dysfunctional beliefs and attitude about sleep.

    Time frame: baseline, 12, 24 and 36 weeks from the baseline

  13. Self-reported Feedback Questionnaire

    Participants experiences from the intervention including habits of practice of the new skills, experience of the effect of the intervention on sleep, mood and lifestyle, alliance with the therapist, the positive and negative effects of the treatment are questioned after the treatment period.

    Time frame: 12 weeks

  14. Objective information on sleep from Actigraphy (ACG) data

    The dataset from ACG includes Total Sleep Time (TST), Wake After Sleep Onset (WASO) Bed time, Get up time, Time in bed, Sleep efficiency (SE), Sleep Onset Latency (SOL), One minute immobility and Fragmentation index

    Time frame: baseline (1 week) and week 12(1 week)

  15. Objective information on circadian rhythms from Actigraphy (ACG) data

    The dataset from ACG includes Cosine peak, Light/Dark ratio, Lowest 5 onset, Maximum 10 onset, RA, IV and IS

    Time frame: baseline (1 week) and week 12(1 week)

  16. Subjective sleep diary tracking

    Each morning after waking participants completed the Sleep Diary during the ACG -monitoring period to provide a daily record of self-reported bedtime, get-up time, sleep duration, and daytime naps.

    Time frame: baseline (1 week) and week 12(1 week)

  17. Objective information on activity from EMFIT Sleep Tracker data (Emfit Ltd)

    EMFIT device measures heart rate, breathing rate, movement activity every 4 seconds, sleep staging every 30 seconds, and heart rate variability every 3 minutes.

    Time frame: baseline to week 13

  18. Objective information on recovery of the autonomic nervous system from EMFIT Sleep Tracker data (Emfit Ltd)

    EMFIT device measures heart rate, breathing rate, movement activity every 4 seconds, sleep staging every 30 seconds, and heart rate variability every 3 minutes.

    Time frame: baseline to week 13

  19. Cognitive performance is measure with the psychomotor vigilance test (PVT) (Basner 2011) via a web-based interface

    PVT is a sustained-attention, reaction-timed task that measures the speed with which subjects respond to a visual stimulus

    Time frame: baseline, 12, 24 and 36 weeks from the baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Basner M, Dinges DF. Maximizing sensitivity of the psychomotor vigilance test (PVT) to sleep loss. Sleep. 2011 May 1;34(5):581-91. doi: 10.1093/sleep/34.5.581. PubMed 21532951 ↗
  • Edinger JD, Carney CE 2015. Overcoming Insomnia: A Cognitive-Behavioral Therapy Approach. Workbook.Oxford University Press 2015
  • Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med. 1999 Jul;29(4):879-89. doi: 10.1017/s0033291799008661. PubMed 10473315 ↗
  • Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4(2):97-110. PubMed 1027738 ↗
  • Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. PubMed 11556941 ↗
  • Lundqvist A, Mäki-Opas T (eds.). Health 2011 Survey - Methods. Terveyden ja hyvinvoinnin laitos, Raportti 8/2016. Helsinki 2016
  • Morin C, Espie C 2003. Insomnia: A clinical Guide to assessment and treatment. New York. Springer.
  • Morin C. 2003. Treating insomnia with behavioral approaches: evidence for efficacy, effectiveness, and practicality. In M. P. Szupa, J.D. Kloss & D.F. Dinges (toim), Insomnia. Principles and Management, s. 73-82. Cambridge University press
  • Morin CM, Vallieres A, Ivers H. Dysfunctional beliefs and attitudes about sleep (DBAS): validation of a brief version (DBAS-16). Sleep. 2007 Nov;30(11):1547-54. doi: 10.1093/sleep/30.11.1547. PubMed 18041487 ↗
  • Morin CM, Belleville G, Belanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011 May 1;34(5):601-8. doi: 10.1093/sleep/34.5.601. PubMed 21532953 ↗
  • Partinen M, Gislason T. Basic Nordic Sleep Questionnaire (BNSQ): a quantitated measure of subjective sleep complaints. J Sleep Res. 1995 Jun;4(S1):150-155. doi: 10.1111/j.1365-2869.1995.tb00205.x. PubMed 10607192 ↗
  • Sandman N, Valli K, Kronholm E, Revonsuo A, Laatikainen T, Paunio T. Nightmares: risk factors among the Finnish general adult population. Sleep. 2015 Apr 1;38(4):507-14. doi: 10.5665/sleep.4560. PubMed 25325474 ↗
  • Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med. 2001 Jul;33(5):328-36. doi: 10.3109/07853890109002086. PubMed 11491191 ↗
  • Tuomi T Ilmarinen J, Jahkola A, Katajarinne l, Tulkki A (1998) Work ability index. Finnish Institute of Occupational Healht, Helsinki
  • Waters F, Ree M ja Chiu V. Delivering CBT for Insomnia in Psychosis - A clinical guide. New York, Routledge, 2017

Individual participant data

Plan to share: No — Upon completion of the clinical trial, data will be made available upon reasonable request and by the review of ethics Committee of the Hospital District of Helsinki and Uusimaa, Finland

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Sep 2024, 56 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 56 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2019
First posted
Oct 30, 2019
StartActual
Dec 19, 2019
Primary completionEst.
Sep 6, 2024
CompletionEst.
Sep 6, 2024
Last update
Oct 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04144231
Collaborators
University of Helsinki, Finnish Institute for Health and Welfare, Finnish Institute of Occupational Health
Responsible party
Tiina M. Paunio (Professor of Psychiatry and Vice Dean of Education / Department of Psychiatry, Faculty of Medicine, University of Helsinki, Research Professor / National Institute for Health and Welfare, Helsinki University Central Hospital) — Principal investigator
First posted
Oct 30, 2019
Start date
Dec 19, 2019
Primary completion
Sep 6, 2024 (estimated)
Completion
Sep 6, 2024 (estimated)
Last update
Oct 10, 2023

Study contacts

Tiina M. Paunio, M.D., Ph.D.
Contact
tiina.paunio@helsinki.fi
+358503507936
Tuula E. Tanskanen, RN, MHC
Contact
tuula.tanskanen@hus.fi
+358401286262
Tiina M. Paunio, M.D., Ph.D.
principal investigator · Helsinki University Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion